Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence
Starting soon
Conditions studied: Cardio Vascular Disease, Acute Coronary Syndromes (ACS), Type 2 Diabetes, Pre Diabetes, Artifical Intelligence
In brief
Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.
Key facts
- Study ID
- NCT07515807
- Run by
- Weill Cornell Medical College in Qatar
- People needed
- 10000
- Starts
- 2026-07-16
- Expected to finish
- 2030-07-16
- Last updated by the study team
- 2026-04-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18
- Qatari and Arab participants
- Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)
- Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%
You may not qualify if…
- Non-Qatari or non-Arab participants
- Non-diabetic: HbA1C < 5.7%
- This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.
Where it is running
- Hamad Medical Corporation — Doha, Qatar
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.